Enveric Biosciences reports new preclinical data supporting non-hallucinogenic profile of lead drug candidate EB-003

Enveric Biosciences released new preclinical results supporting a non-hallucinogenic profile for lead candidate EB-003.

Findings were presented now, based on live-cell testing that compared EB-003 with hallucinogenic and non-hallucinogenic reference compounds.

Data aligned with recent published research linking specific receptor signaling patterns to hallucinogenic risk, placing EB-003 in a non-hallucinogenic range.

Results support plans to move EB-003 into a first-in-human Phase 1 trial, a key step toward clinical validation.

A non-hallucinogenic profile could simplify trial execution, improve blinding, reduce monitoring burdens, support an outpatient model, and expand commercial scalability.